Don’t miss Jin Ju Lee tomorrow at #ASTRO26 as she shares radiation therapists’ perspectives on gaps in pretreatment patient education for radiation therapy during a Quick Pitch session. #MoffittASTRO26 @ASTRO_org

At #ASTRO26, Kolade Olabode, MD (@Kolade__Olabode) stops by the booth to present his poster on stage II-III NSCLC, with TP53 and BRCA2 mutations emerging as key genomic predictors of brain metastasis risk. A genomics-based model successfully identified high- and low-risk groups. Further study of molecular profiling for risk-adapted surveillance is needed. #MoffittASTRO26

Tomorrow at #ASTRO26, John Peterson, MD (@John_S_Pete), shares findings on CT-based adaptive radiotherapy for inoperable pancreatic cancer, including dosimetric outcomes and clinical toxicity. #MoffittASTRO26 @ASTRO_org

🚨NEW from #ASTRO26: The phase 3 NRG-CC009 trial found median overall survival was 17.4 months with stereotactic radiosurgery vs. 8.6 months with hippocampal-avoidant whole-brain radiation for patients with small cell lung cancer and brain metastases. Moffitt’s Kolade Olabode, MD (@Kolade__Olabode), breaks down the findings and what they could mean for individualized treatment decisions. #MoffittASTRO26

From the #ASTRO26 poster session, Glebys Gonzalez, PhD, shares a dose-informed AI model that improved spatial radiation dose prediction from in vivo acoustic signals, outperforming conventional methods in preliminary patient testing. The model also demonstrated computational efficiency compatible with future real-time dose prediction workflows. #MoffittASTRO26

Don’t miss Evan Wuthrick, MD, (@EvanWuthrick) tomorrow afternoon at #ASTRO26 as he shares an educational overview of evolving radiotherapy strategies for high-risk cutaneous squamous cell carcinoma. #MoffittASTRO26 @ASTRO_org

LIVE from the #ASTRO26 presidential address: @ASTRO_org President Neha Vapiwala, MD (@NehaVapiwala), shares her vision for the organization, including advancing radiotherapy care and strengthening professional development to better serve patients. #MoffittASTRO26

The #ASTRO26 plenary is about to begin! We’re looking forward to hearing the latest scientific findings and data advancing the field of radiation oncology. Follow #MoffittASTRO26 for key insights from the session. @ASTRO_org

#LIVE from the #ASTRO26 plenary: Guang-Yi Sun, MD, opens the session with 10-year findings showing hypofractionated postmastectomy radiotherapy provided comparable disease control and survival to conventional fractionation in high-risk breast cancer, with acceptable long-term toxicity. The findings support hypofractionation as a safe and efficient treatment option. #MoffittASTRO26

🚨 New research being presented at #ASTRO26 provides randomized phase 3 evidence supporting fractionated radiosurgery for larger postoperative brain metastasis cavities. Moffitt’s Raj Upadhyay, MD (@aiims2738), discusses findings from the Alliance A071801 trial and what they could mean for improving local control and refining treatment for patients with brain metastases. #MoffittASTRO26 @ASTRO_org

Tomorrow at #ASTRO26, Samantha Webking, MD, shares the latest on a cross-continental evaluation of a multimodal AI-based biomarker for localized prostate cancer during the poster session. #MoffittASTRO26 @ASTRO_org

#LIVE from the #ASTRO26 plenary: Theodore Hong, MD, of @DanaFarberNews presents initial results from the phase 3 NRG-GI003 trial, which found no significant advantage with proton therapy over photon therapy for overall survival, progression-free survival or local control in advanced hepatocellular carcinoma. Grade 3 or higher treatment-related adverse events were less frequent with protons, but the difference was not statistically significant. #MoffittASTRO26

Don’t miss Celina Chiodo, MD (@celinachiodo), tomorrow at #ASTRO26 as she shares findings comparing outcomes of trimodality therapy for muscle-invasive bladder cancer across different tumor histologies. #MoffittASTRO26 @ASTRO_org

LIVE from the #ASTRO26 plenary: Ayal Aizer, MD, of @BrighamWomens highlights results from the phase 3 Alliance A071801 trial, showing that fractionated SRS improved surgical bed control and overall survival compared with single-fraction SRS after resection of larger brain metastases, with no significant difference in adverse events. #MoffittASTRO26

Live from the #ASTRO26 plenary: Chad Rusthoven, MD, of @CUAnschutz, presents phase 3 results showing SRS improved overall survival compared with hippocampal-avoidant whole-brain radiotherapy for small cell lung cancer with brain metastases, with similar neurocognitive and CNS outcomes. Findings support SRS as a standard-of-care option. #MoffittASTRO26

Tomorrow at #ASTRO26, Dekuang Zhao, DO (@DK_18621), shares the latest on circulating tumor DNA dynamics in oligometastatic urothelial carcinoma treated with stereotactic body radiation therapy. #MoffittASTRO26 @ASTRO_org

From #ASTRO26, Kamran Ahmed, MD (@KAhmedMD), presents a phase 2 study of SBRT followed by atezolizumab in advanced cervical cancer that demonstrated a 38% response rate in unirradiated tumors, including responses in PD-L1-negative disease. Long-term analysis also identified circulating immune biomarkers associated with treatment response. #MoffittASTRO26

Don’t miss Jessica Frakes, MD (@JessicaFrakesMD), tomorrow at #ASTRO26 as she moderates a scientific session exploring particles, protection and priming in pancreatic and hepatobiliary cancers. #MoffittASTRO26 @ASTRO_org

Tomorrow at #ASTRO26, Dipesh Niraula, PhD (@dipeshniraula_), shares the latest on the association between radiation dose to cardiac substructures and survival in patients with NSCLC treated with concurrent chemoradiotherapy. #MoffittASTRO26 @ASTRO_org

Tomorrow at #ASTRO26, Levi Martinka, MD (@LeviMartinka3), shares findings on the prognostic impact of comprehensive genomic profiling by STK11 status in patients with NSCLC treated with the PACIFIC regimen. #MoffittASTRO26 @ASTRO_org